The post Hyperscale Data Launches $125 Million ATM Stock Issuance appeared on BitcoinEthereumNews.com. Key Points: Hyperscale Data seeks to raise $125 million through ATM stock issuance. Funds directed towards Bitcoin, XRP acquisition, and facility expansion. NYSE-listed effort mirrors corporate interest in digital assets. Hyperscale Data, a New York Stock Exchange-listed company, announced its “At-The-Market” stock issuance plan to raise $125 million to purchase Bitcoin, XRP, and expand its Michigan data facility. This move highlights traditional companies increasing crypto asset holdings, potentially affecting Bitcoin and XRP markets, and signifies evolving corporate strategies within the digital currency space. $125 Million Stock Issuance Targets Crypto Acquisition Hyperscale Data announced a $125 million At-The-Market stock issuance plan, involving Wilson-Davis & Co., Inc. as the sales agent to raise funds. These proceeds are partially earmarked for purchasing Bitcoin and XRP, with additional investments allocated to expanding their Michigan data facility. Immediate changes involve incorporating digital assets like Bitcoin and XRP into the company’s treasury, aligning with a growing trend among publicly traded corporations. Such acquisitions often enhance operational capacity, facilitating strategic growth and attracting stakeholders. The market shows positive reactions, but no direct statements from top industry figures are currently noted. Community interest is growing, as observed on developer platforms, anticipating further corporate adoption of cryptocurrencies. Monitoring Hyperscale Data’s official channels is recommended for real-time updates. “As of the current search, no direct quotes from key players, leadership, or experts related to the announcement from Hyperscale Data have been recovered. However, for the most accurate and timely information regarding this announcement, I recommend monitoring the following channels: Corporate Communications: Hyperscale Data’s official press releases on their corporate website and their regulatory filings with the SEC. Investor relations pages and social media accounts (e.g., LinkedIn and Twitter). Market Commentary: Leading voices in the crypto space on social media (Twitter/X) for real-time reactions, including notable figures such as Arthur Hayes,… The post Hyperscale Data Launches $125 Million ATM Stock Issuance appeared on BitcoinEthereumNews.com. Key Points: Hyperscale Data seeks to raise $125 million through ATM stock issuance. Funds directed towards Bitcoin, XRP acquisition, and facility expansion. NYSE-listed effort mirrors corporate interest in digital assets. Hyperscale Data, a New York Stock Exchange-listed company, announced its “At-The-Market” stock issuance plan to raise $125 million to purchase Bitcoin, XRP, and expand its Michigan data facility. This move highlights traditional companies increasing crypto asset holdings, potentially affecting Bitcoin and XRP markets, and signifies evolving corporate strategies within the digital currency space. $125 Million Stock Issuance Targets Crypto Acquisition Hyperscale Data announced a $125 million At-The-Market stock issuance plan, involving Wilson-Davis & Co., Inc. as the sales agent to raise funds. These proceeds are partially earmarked for purchasing Bitcoin and XRP, with additional investments allocated to expanding their Michigan data facility. Immediate changes involve incorporating digital assets like Bitcoin and XRP into the company’s treasury, aligning with a growing trend among publicly traded corporations. Such acquisitions often enhance operational capacity, facilitating strategic growth and attracting stakeholders. The market shows positive reactions, but no direct statements from top industry figures are currently noted. Community interest is growing, as observed on developer platforms, anticipating further corporate adoption of cryptocurrencies. Monitoring Hyperscale Data’s official channels is recommended for real-time updates. “As of the current search, no direct quotes from key players, leadership, or experts related to the announcement from Hyperscale Data have been recovered. However, for the most accurate and timely information regarding this announcement, I recommend monitoring the following channels: Corporate Communications: Hyperscale Data’s official press releases on their corporate website and their regulatory filings with the SEC. Investor relations pages and social media accounts (e.g., LinkedIn and Twitter). Market Commentary: Leading voices in the crypto space on social media (Twitter/X) for real-time reactions, including notable figures such as Arthur Hayes,…

Hyperscale Data Launches $125 Million ATM Stock Issuance

Key Points:
  • Hyperscale Data seeks to raise $125 million through ATM stock issuance.
  • Funds directed towards Bitcoin, XRP acquisition, and facility expansion.
  • NYSE-listed effort mirrors corporate interest in digital assets.

Hyperscale Data, a New York Stock Exchange-listed company, announced its “At-The-Market” stock issuance plan to raise $125 million to purchase Bitcoin, XRP, and expand its Michigan data facility.

This move highlights traditional companies increasing crypto asset holdings, potentially affecting Bitcoin and XRP markets, and signifies evolving corporate strategies within the digital currency space.

$125 Million Stock Issuance Targets Crypto Acquisition

Hyperscale Data announced a $125 million At-The-Market stock issuance plan, involving Wilson-Davis & Co., Inc. as the sales agent to raise funds. These proceeds are partially earmarked for purchasing Bitcoin and XRP, with additional investments allocated to expanding their Michigan data facility.

Immediate changes involve incorporating digital assets like Bitcoin and XRP into the company’s treasury, aligning with a growing trend among publicly traded corporations. Such acquisitions often enhance operational capacity, facilitating strategic growth and attracting stakeholders.

The market shows positive reactions, but no direct statements from top industry figures are currently noted. Community interest is growing, as observed on developer platforms, anticipating further corporate adoption of cryptocurrencies. Monitoring Hyperscale Data’s official channels is recommended for real-time updates.

Historical Moves Resonate as Bitcoin Trades at $108,949.98

Did you know? Hyperscale Data’s interest in BTC and XRP mirrors past moves by firms like MicroStrategy and Tesla, catalyzing mainstream acceptance of digital assets as legitimate balance sheet components.

According to CoinMarketCap, Bitcoin trades at $108,949.98, with a market cap of approximately $2.17 trillion and a 57.24% dominance. The 24-hour volume is $46.88 billion, a 16.37% decrease. Prices changed by 0.14% over the past day and observed shifts over longer periods: -2.61% for seven days, -3.78% for thirty days, -0.52% for sixty days, and a positive 4.07% for ninety days. The circulating supply stands at 19,914,328 with a maximum supply of 21 million as of August 31, 2025.

Bitcoin(BTC), daily chart, screenshot on CoinMarketCap at 20:08 UTC on August 31, 2025. Source: CoinMarketCap

Coincu experts suggest this fundraising reflects wider institutional confidence in cryptocurrency’s growth potential, focusing on Bitcoin and XRP enhances liquidity and market capitalization, indicating market maturity and regulatory acceptance trends.

Source: https://coincu.com/news/hyperscale-data-atm-stock-issuance-bitcoin/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26